VIENNA--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX), a global leader in acute care therapies, announced today the commercial launch of a new indication for the company’s oXiris set, which ...

“We are doing whatever it takes to support healthcare providers as they care for patients during extraordinary circumstances. Oxiris offers a new tool in the COVID-19 fight while supplementing our ...

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in acute care, today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s ST ...

Baxter International, a global leader in acute care, announced it has received Emergency Use Authorizations (EUAs) from the US Food and Drug Administration (FDA) for the company’s HF20 Set and ST Set ...

Baxter International Inc. BAX recently received Emergency Use Authorization (EUA) from the FDA for Regiocit, which is the only authorized citrate-based replacement solution available in the United ...

The U.S. FDA has granted emergency use authorizations (EUAs) to Baxter International Inc. for its HF20 Set and ST Set used in continuous renal replacement therapy (CRRT) during the COVID-19 pandemic.

MISSISSAUGA, ON, July 10, 2018 /CNW/ - Baxter Canada today announced Health Canada's approval of a new indication for the company's oXiris set, which can now be used to help remove excessive levels of ...

The U.S. FDA has granted emergency use authorizations (EUAs) to Baxter International Inc. for its HF20 Set and ST Set used in continuous renal replacement therapy (CRRT) during the COVID-19 pandemic.

In comparison to the flood of emergency use authorizations doled out by the FDA throughout the COVID-19 pandemic, the number of those tests and devices that have gone on to receive full, non-pandemic ...

* Has approved the admission to trading's request on Alternext Paris for the ordinary shares representing the outstanding share capital of Prismaflex International Sign up here. * After the end of the ...